Neoadjuvant modified TPF (docetaxel, cisplatin, fluorouracil) for patients unfit to standard TPF in locally advanced head and neck squamous cell carcinoma: a study of 48 patients

TPF (docetaxel, cisplatin, fluorouracil) is the standard chemotherapy used for induction in locally advanced head and neck squamous cell carcinoma (LAHNSCC). Its toxicity limits it to younger patients with good functional status and without significant comorbidity. Since modified TPF (mTPF) demonstr...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Cyhoeddwyd yn:Oncotarget
Prif Awduron: Fayette, Jérôme, Fontaine-Delaruelle, Clara, Ambrun, Alexis, Daveau, Clémentine, Poupart, Marc, Ramade, Antoine, Zrounba, Philippe, Neidhardt, Eve-Marie, Péron, Julien, Diallo, Alpha, Céruse, Philippe
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: Impact Journals LLC 2016
Pynciau:
Clinical Research Paper
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC5095077/
https://ncbi.nlm.nih.gov/pubmed/27119503
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.8934
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg